Candidiasis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Candidiasis Therapeutics Market is Segmented by Route of Administration (Injection, Ointment, and Oral), Drug Type, Anatomy Type, End-user, and Geography.

Market Snapshot

Candidiasis Therapeutics Market_image1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The candidiasis therapeutics market is expected to witness rapid growth due to the increase in the number of patients affected by candidiasis infection, an increase in the susceptible immune-compromised patient pool, and growing awareness for candidiasis infection.

There has been an increase in the number of patients affected by candidiasis infection in the developing markets, which may boost the overall market growth over the forecast period. The Center for Disease Control and Prevention (CDC) estimates that approximately 46,000 cases of healthcare-associated invasive candidiasis occur each year, in the United States. CDC reports that the 30-day all-cause (crude) mortality among people with candidemia is approximately 30%. However, as people who develop invasive candidiasis typically have pre-medical conditions, it is generally ambiguous to determine the proportion of deaths directly attributable to the infection. This increase in the number of patients has helped in spurring the growth of the overall market. The increasing urbanization and rising hygiene awareness in developing countries may also help in the growth of the market.

Scope of the Report

As per the scope of the report, candidiasis is a fungal infection that affects men and women, both, of all age groups. It is also known as candidosis, moniliasis, and oidiomycosis. The effects of this infection are seen on a dermal, internal, and systemic level, wherein it is known as candidemia or intestinal thrush. The market is dynamic due to the widespread occurrence of this disease. The major drug classes for the treatment include azoles, polyenes, and echinocandins.

By Route of Administration
Injection
Ointment
Oral
By Drug Type
Polyene
Azole
Echinocandin
Other Types of Drugs
By Anatomy Type
Oral Candidiasis
Vulvovaginal Candidiasis
Cutaneous Candidiasis
Invasive Candidiasis
Systemic Candidiasis
By End-user
Hospitals
Clinics
Retail Pharmacies
Drug Stores
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Systemic Candidiasis under the Anatomy Type Segment is Anticipated to Dominate the Market during the Forecast Period

The market for systemic candidiasis is driven by the increase in the susceptible immune-compromised patient pool. Thrush occurs in approximately 2-5% of healthy newborns and affects them mainly during their first year of life. Over 1 million adult women and adolescent girls in the United States develop vaginal yeast infections each year. Therefore, the high incidence rate of candidiasis is expected to remain a major driver for the growth of the market, during the forecast period.

1

North America Region Holds the Largest Market Share

Due to the high investment in healthcare and awareness of diseases, the North American segment of the market studied is estimated to account for the highest market share. The candidiasis disease is growing rapidly in the United States and is not restricted to any particular region. Additionally, the North American and European regions accounted for the largest market revenue shares, due to higher awareness of the disease among individuals and the availability of better treatment. Hence, all these factors are likely to boost the market growth.

Candidiasis Therapeutics Market geo.png

Competitive Landscape

The market studied is moderately competitive and there is a presence of local as well as international companies in te market studied. The major companies operating in the market are focusing on product innovations, expansions, finding new markets, or innovating their core competency to expand their individual market share.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Number of Patients Affected by Candidiasis Infection

      2. 4.2.2 Growing Awareness for Candidiasis Infection

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of Alternative Treatments

      2. 4.3.2 Narrow Pipeline Molecules

      3. 4.3.3 Competition from Herbal Medicines and Alternate Therapies

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Injection

      2. 5.1.2 Ointment

      3. 5.1.3 Oral

    2. 5.2 By Drug Type

      1. 5.2.1 Polyene

      2. 5.2.2 Azole

      3. 5.2.3 Echinocandin

      4. 5.2.4 Other Types of Drugs

    3. 5.3 By Anatomy Type

      1. 5.3.1 Oral Candidiasis

      2. 5.3.2 Vulvovaginal Candidiasis

      3. 5.3.3 Cutaneous Candidiasis

      4. 5.3.4 Invasive Candidiasis

      5. 5.3.5 Systemic Candidiasis

    4. 5.4 By End-user

      1. 5.4.1 Hospitals

      2. 5.4.2 Clinics

      3. 5.4.3 Retail Pharmacies

      4. 5.4.4 Drug Stores

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East & Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle-East & Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Basilea Pharmaceuticals

      2. 6.1.2 Astellas

      3. 6.1.3 Ferrer Internacional

      4. 6.1.4 Pacgen Biopharmaceuticals

      5. 6.1.5 NovaDigm Therapeutics

      6. 6.1.6 Pevion Biotech

      7. 6.1.7 Amplyx Pharmaceuticals Inc.

      8. 6.1.8 Biomar Microbial Technologies

      9. 6.1.9 Cidara Therapeutics Inc.

      10. 6.1.10 Novabiotics Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Candidiasis Therapeutics Market market is studied from 2018 - 2026.

The Candidiasis Therapeutics Market is growing at a CAGR of 5.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Basilea Pharmaceuticals, Astellas, Ferrer Internacional, Pacgen Biopharmaceuticals, NovaDigm Therapeutics are the major companies operating in Candidiasis Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!